Literature DB >> 2905187

Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group.

.   

Abstract

In a prospective, randomized multicentre trial the efficacy and safety of the low molecular weight heparin (LMWH) fraction Fraxiparin and unfractionated calcium heparin (Calciparin) were compared for the prevention of postoperative deep vein thrombosis. Of 1909 patients included in the trial 1896 underwent abdominal surgery and received either one daily subcutaneous injection of 7500 anti-Xa units Fraxiparin or 5000 units calcium heparin three times a day subcutaneously. Elastic compression stockings were worn by both groups of patients in the postoperative period. Before randomization the patients were stratified in two subgroups with or without malignant disease. To assess the rate of deep vein thrombosis (DVT), 125I-labelled fibrinogen leg scanning was performed daily for 7 postoperative days. Positive results were confirmed by phlebography whenever possible. Venous thrombosis occurred in 27 of 960 patients (2.8 per cent) given Fraxiparin and in 42 of 936 patients (4.5 per cent) given calcium heparin (P = 0.034). The rates of proximal vein thrombosis were 0.4 per cent (4 patients) and 1.4 per cent (13 patients) respectively (P less than 0.05). Pulmonary embolism occurred in 2 of 960 patients (0.2 per cent) treated with Fraxiparin and in 5 of 936 patients (0.5 per cent) treated with calcium heparin. The two treatments were equally well tolerated. Intra- and postoperative blood loss, the number of wound haematomas as well as frequency and volume of transfusions were similar in both groups. The present trial demonstrates that a single daily subcutaneous injection of Fraxiparin is more effective than the established low dose subcutaneous heparin prophylaxis with 5000 units three times per day in preventing postoperative DVT after abdominal surgery in patients wearing compression stockings.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905187     DOI: 10.1002/bjs.1800751105

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  22 in total

Review 1.  The use of meta-analysis in cost-effectiveness analysis. Issues and recommendations.

Authors:  S Saint; D L Veenstra; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

Review 2.  [Physical prophylaxis for thromboembolism. Current state of knowledge on use of medical thromboprophylaxis stockings].

Authors:  P Kujath; M Hoffmann
Journal:  Chirurg       Date:  2013-12       Impact factor: 0.955

Review 3.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 4.  Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update.

Authors:  Michela Falciani; Davide Imberti; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 5.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 6.  Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.

Authors:  K Wellington; K McClellan; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis.

Authors:  J Limmer; D Ellbrück; H Müller; E Eisele; J Rist; F Schütze; H Beger; H Heimpel; E Seifried
Journal:  Clin Investig       Date:  1994-11

8.  Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen.

Authors:  D Voth; M Schwarz; K Hahn; K Dei-Anang; S al Butmeh; H Wolf
Journal:  Neurosurg Rev       Date:  1992       Impact factor: 3.042

9.  Predictive value of fibrin monomers in postoperative deep vein thrombosis.

Authors:  G Vogel; E Spanuth
Journal:  Klin Wochenschr       Date:  1990-10-17

Review 10.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.